Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

SOMERSET, N.J., Oct. 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the fourth quarter and fiscal year ended July 31, 2008.

The company recorded a net loss of approximately $2.9 million, or $0.06 per basic and diluted common share, for the fourth fiscal quarter ended July 31, compared to a net loss of approximately $2.4 million, or $0.05 per basic and diluted common share, for the fourth quarter of fiscal 2007. Research and development expenses increased by approximately $0.9 million during the fourth quarter of fiscal 2008 as compared to the same quarter a year ago primarily due to expenses incurred related to the company's preparations for the completion of its ONCONASE(R) rolling New Drug Application (NDA) submission. Decreased general and administrative expenses of approximately $0.5 million for the fourth quarter of fiscal 2008 were primarily the result of reduced stock based compensation expenses.

Net loss for the fiscal year ended July 31, 2008 of approximately $12.3 million, or $0.26 per basic and diluted common share, represents an increase of approximately $3.5 million, compared to the $8.8 million net loss, or $0.19 per basic and diluted common share, for fiscal 2007.

Cash and Liquidity

As of July 31, 2008, the company had cash and cash equivalents of approximately $4.7 million, a decrease of approximately $3.1 million, compared to cash and cash equivalents of approximately $7.8 million on April 30, 2008. The company has received notification that it continues to qualify for the sale of its state tax loss carryforwards in New Jersey and is awaiting additional information on the proceeds it can expect to receive from this sale in late 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... Aug. 31, 2015 LabStyle Innovations Corp. ... Solution, today announced it recently closed a round ... be used to support the global rollout and ... mobile, cloud-based, diabetes management solution that includes novel ... blood glucose monitoring device, and for working capital ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... ... (PGIs), as a high priority in the drug development approval process. Thus, innovator ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Sept. 17 Synvista,Therapeutics, Inc. (Amex: SYI ) ... to the Company,s Web site http://www.synvista.com . The,text ... team at Synvista Therapeutics has made tremendous progress in ... and to redefine,the treatment of cardiovascular disease in diabetics ...
... Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will be presenting ... September 24th at 8:30 AM ET at the Grand ... live audio broadcast over the,Internet available at http://ir.sigmaaldrich.com ... file. For the webcast on, http://ir.sigmaaldrich.com users will ...
... Alfacell Corporation,(Nasdaq: ACEL ) announced today ... of Oppenheimer & Co. as a financial advisor ... alternatives to enhance,shareholder value, including a possible sale ... not be limited to, strategic partnership,transactions., "Alfacell ...
Cached Biology Technology:Synvista Therapeutics Posts Letter to Stockholders on Web Site 2Synvista Therapeutics Posts Letter to Stockholders on Web Site 3Synvista Therapeutics Posts Letter to Stockholders on Web Site 4Synvista Therapeutics Posts Letter to Stockholders on Web Site 5Synvista Therapeutics Posts Letter to Stockholders on Web Site 6Alfacell Hires Advisors to Advance Strategic Alternatives 2Alfacell Hires Advisors to Advance Strategic Alternatives 3
(Date:8/12/2015)... 2015  New research unveiled at Black Hat ... to steal users, fingerprints. Information released today by ... scanners on mobile devices, making the security of ... on mobile devices, HYPR Corp. recently released a ... systems with strong cryptographic security. More information on ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... wheat ( Triticum aestivum ) is one of the "big ... consumed by people. Fully 35% of the world,s 7 billion ... international team of scientists, including a group from Cold Spring ... its full genome. The study reveals the evolution ...
... a surprise to hear that most adult entertainment club workers ... bartenders, waitresses and hostesses don,t have great medical benefits. ... repeated unwanted sexual advances and behavior. Add in the prevalence ... a perfect storm for unchecked health risks. To ...
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
Cached Biology News:Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3Rhode Island Hospital: Adult entertainment workers likely to benefit from health care intervention 2
Human Cell Line Slides...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: